ACTION ON FISTULA™ has transformed the lives of over 3,6661 women in Kenya who are suffering with obstetric fistula. The programme was started in 2014 by a grant* given to the Fistula Foundation from Astellas Pharma Europe Ltd, with the aim of helping more than 4,500 women access treatment by 20202. ACTION ON FISTULA allows surgeons, outreach workers and hospitals to share resources and information as well as treat women with the highest levels of care.
Fistula Foundation and Astellas are committed to ending suffering from obstetric fistula, but support from other organisations is urgently needed to meet the 2020 goals. ACTION ON FISTULA is seeking supporters and interested parties should contact the Fistula Foundation via www.fistulafoundation.org.
Astellas Pharma Europe Ltd is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals.
 As of May 2018
2 Pharmafield, Action on Fistula to transform 4,500 lives by 2020, at www.pharmafield.co.uk/pharma_news/action-on-fistula-to-transform-4500-lives-by-2020/ last accessed June 2018
*Astellas contributed €1.5 million to set up and run the programme for the first phase of ACTION ON FISTULA, which ran from 2014 to 2017. The second phase of ACTION ON FISTULA™ is a €3 million programme from 2017 to 2020, run by Fistula Foundation. It is part-funded by a €750,000 grant and additional in-kind support and employee fundraising from Astellas, with the remainder being generated by Fistula Foundation. Astellas is therefore one of several contributors to the Fistula Foundation. Fistula Foundation is constantly seeking additional contributors to raise additional funds to help meet the programme’s ambitious goals.